Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
FBLG 
FibroBiologics, Inc. Common Stock (FBLG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: FBLG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.25
1 Year Target Price $10.25
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.51% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.17M USD | Price to earnings Ratio - | 1Y Target Price 10.25 |
Price to earnings Ratio - | 1Y Target Price 10.25 | ||
Volume (30-day avg) 3 | Beta - | 52 Weeks Range 0.39 - 3.89 | Updated Date 10/17/2025 |
52 Weeks Range 0.39 - 3.89 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.36 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -88.11% | Return on Equity (TTM) -559.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 24551136 | Price to Sales(TTM) - |
Enterprise Value 24551136 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 41889142 | Shares Floating 32066138 |
Shares Outstanding 41889142 | Shares Floating 32066138 | ||
Percent Insiders 19.57 | Percent Institutions 12.3 |
Upturn AI SWOT
FibroBiologics, Inc. Common Stock
Company Overview
History and Background
FibroBiologics, Inc. is a biotechnology company focused on the development of fibroblast-based therapies for chronic diseases. Founded in 2015, it has achieved milestones in developing novel cell therapies and securing patents for its technology. The company continues to evolve through clinical trials and strategic partnerships.
Core Business Areas
- Fibroblast Cell Therapy Development: Focuses on developing fibroblast-based cell therapies for a range of degenerative diseases and conditions.
- Regenerative Medicine Research: Conducts research to advance the understanding and application of regenerative medicine principles.
- Intellectual Property Portfolio: Building a strong intellectual property portfolio around its fibroblast technologies.
Leadership and Structure
The company is led by a team of experienced biotechnology executives and scientists. The organizational structure includes research and development, clinical operations, and corporate management departments.
Top Products and Market Share
Key Offerings
- FibroGenesisu2122: FibroGenesisu2122 is a proprietary fibroblast technology platform. FibroBiologics aims to use it for various degenerative conditions. Market share information is not publicly available as the products are in development. Competitors include companies developing cell therapies for regenerative medicine.
- Cell-Based Therapies (pre-clinical): A portfolio of preclinical cell-based therapy candidates targeting diverse chronic diseases. Market share information is not publicly available at this early stage. Competitors are other regenerative medicine companies.
Market Dynamics
Industry Overview
The regenerative medicine industry is experiencing rapid growth, driven by increasing demand for novel therapies to treat chronic diseases. The field is characterized by intense research and development activity, regulatory hurdles, and significant investment.
Positioning
FibroBiologics is positioned as an innovator in the fibroblast cell therapy space. Its competitive advantage lies in its proprietary technology and focus on specific disease targets.
Total Addressable Market (TAM)
The total addressable market for regenerative medicine is estimated to be in the billions of dollars. FibroBiologics is aiming to capture a share of this market through the successful development and commercialization of its cell therapies. Specific figures for TAM are not disclosed.
Upturn SWOT Analysis
Strengths
- Proprietary FibroGenesisu2122 technology platform
- Experienced management team
- Focus on innovative cell therapies
- Strong intellectual property position
Weaknesses
- Early stage of development
- Limited clinical data
- High cash burn rate
- Dependence on securing further funding
Opportunities
- Expanding applications of FibroGenesisu2122 technology
- Strategic partnerships and collaborations
- Advancements in regenerative medicine
- FDA approval pathways for cell therapies
Threats
- Regulatory hurdles
- Competition from established biotech companies
- Clinical trial failures
- Difficulty in securing funding
Competitors and Market Share
Key Competitors
- JNJ
- BMY
- GILD
Competitive Landscape
FibroBiologics faces competition from established biotech and pharmaceutical companies with greater resources and experience. Its competitive advantage lies in its innovative technology and focus on specific disease targets.
Growth Trajectory and Initiatives
Historical Growth: The company's growth has been driven by progress in research and development and securing funding.
Future Projections: Future growth is dependent on successful clinical trials and commercialization of its cell therapies.
Recent Initiatives: Recent initiatives include advancing clinical trials and exploring strategic partnerships.
Summary
FibroBiologics is a promising biotechnology company with an innovative cell therapy platform, but it faces significant challenges related to funding, regulatory approval, and competition. Its strengths lie in its proprietary technology and experienced management team. Success will depend on achieving positive clinical trial results and securing strategic partnerships, however it is a very small private company competing against Giants.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Public financial databases for listed competitors
Disclaimers:
The information provided is based on publicly available data and limited information due to the company being private. The analysis is for informational purposes only and does not constitute investment advice. Financial data on FibroBiologics, Inc. is limited as they are not a publicly traded company.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About FibroBiologics, Inc. Common Stock
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2024-01-31 | Founder, Chairperson & CEO Mr. Peter O'Heeron | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.fibrobiologics.com |
Full time employees 13 | Website https://www.fibrobiologics.com | ||
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The company was founded in 2021 and is based in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.